1. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
- Author
-
Vinti L, Pagliara D, Buffardi S, Di Ruscio V, Stocchi F, Mariggiò E, Parasole R, Di Matteo A, Petruzziello F, Paganelli V, De Vito R, Del Bufalo F, Strocchio L, and Locatelli F
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bendamustine Hydrochloride adverse effects, Brentuximab Vedotin, Child, Humans, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local etiology, Retrospective Studies, Treatment Outcome, Young Adult, Hodgkin Disease pathology, Immunoconjugates therapeutic use
- Abstract
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m
2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively., (© 2022 Wiley Periodicals LLC.)- Published
- 2022
- Full Text
- View/download PDF